Radionetics Oncology has entered into a strategic collaboration with Eli Lilly to advance their G protein-coupled receptor (GPCR) targeting small molecule radiopharmaceuticals for treating solid tumors
As per the agreement, Radionetics obtained a payment of $140M upfront in cash while Eli Lilly received an exclusive right to acquire Radionetics for an aggregate of $1B post exercise period
Radionetics will develop a novel pipeline of GPCR targeting small molecule radioligand therapeutics by leveraging its discovery platform during the exercise period
Ref: Aktis Oncology | Image: Aktis Oncology
Related News:- Aktis Oncology and Eli Lilly Collaborate to Discover and Develop Novel Anticancer Radiopharmaceuticals
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
